Skip to main content

General review publications

General review publications
Prospective Evaluation of Fetal Hemoglobin Expression in Maternal Erythrocytes: An Analysis of a Cohort of 345 Parturients
The objectives of this study were met to document HbF expression during peri and postpartum periods, to confirm its maternal origin, and to assess clinical and biochemical parameters potentially associated with HbF modulation. To our knowledge, this study depicts the largest cohort description of the expression of HbF in pregnant women. 
 
Blain L, Watier C, Weng X, Masse A, Bédard M-J, Bettache N, Weber F, Mahone M, Forté S, Lavallée V-P, Gaudreau P-O, Newmarch MJ, Soulières D. Prospective Evaluation of Fetal Hemoglobin Expression in Maternal Erythrocytes: An Analysis of a Cohort of 345 Parturients. Diagnostics 13: 1873. 2023.
https://www.mdpi.com/2075-4418/13/11/1873
 
An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic.
Cancer in the lungs can be treated with drugs that use your immune system to kill cancer. This study showed that patients lived longer when the drugs were given further apart, and that the extended treatment was equally safe as the standard dosing schedule.
 
Moffat GT, Hanna L, Hopman W, Fung AS, Gaudreau P-O. An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic. Immunotherapy 15: 921-932. 2023.
https://doi.org/10.2217/imt-2022-0257
 

Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations

Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations (ONLINE). ESMO Open 9: 103649. 2024.

Highlights include: Testing exciting new treatments before curative therapy may offer the best chance of increasing cure rates. Researchers must ensure patient safety and minimize over/undertreatment, or denial of standard curative treatments. MDICT developed recommendations for early-phase trials conducted before curative therapy. Patient engagement in the design and conduct of these trials is critical to ensure equipoise. Careful review (risk–benefit), randomization (to reduce bias), and appropriate endpoints are required.